Oncogenic KRAS-dependent stromal interleukin-33 directs the pancreatic microenvironment to promote tumor growth

  • Cancer Discov. 2024 Jul 3. doi: 10.1158/2159-8290.CD-24-0100.
Katelyn L Donahue  1 Hannah R Watkoske  2 Padma Kadiyala  3 Wenting Du  2 Kristee Brown  4 Michael K Scales  1 Ahmed M Elhossiny  3 Carlos E Espinoza  5 Emily L Lasse Opsahl  5 Brian D Griffith  6 Yukang Wen  6 Lei Sun  2 Ashley Velez-Delgado  5 Nur M Renollet  1 Jacqueline Morales  5 Nicholas M Nedzesky  6 Rachael K Baliira  3 Rosa E Menjivar  5 Paola I Medina-Cabrera  1 Arvind Rao  5 Benjamin Allen  3 Jiaqi Shi  3 Timothy L Frankel  2 Eileen S Carpenter  3 Filip Bednar  1 Yaqing Zhang  2 Marina Pasca di Magliano  3
Affiliations
  • 1. University of Michigan-Ann Arbor, Ann Arbor, Michigan, United States.
  • 2. University of Michigan Medical School, Ann Arbor, MI, United States.
  • 3. University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
  • 4. University of Michigan Medical Schooligan, United States.
  • 5. University of Michigan-Ann Arbor, Ann Arbor, United States.
  • 6. University of Michigan-Ann Arbor, United States.
Abstract

Pancreatic Cancer is characterized by an extensive fibroinflammatory microenvironment. During carcinogenesis, normal stromal cells are converted to cytokine-high Cancer associated fibroblasts (CAFs). The mechanisms underlying this conversion, including regulation and function of fibroblast-derived cytokines, are poorly understood. Thus, efforts to target CAFs therapeutically have so far failed. Here, we show that signals from epithelial cells expressing oncogenic KRAS -a hallmark pancreatic Cancer mutation- activate fibroblast autocrine signaling, which drives expression of the cytokine interleukin-33 (IL-33). Stromal IL-33 expression remains high and dependent on epithelial KRAS throughout carcinogenesis; in turn, environmental stress induces IL-33 secretion. Using compartment-specific IL-33 knockout mice, we observed that lack of stromal IL-33 leads to profound reprogramming of multiple components of the pancreatic tumor microenvironment, including CAFs, myeloid cells and lymphocytes. Notably, loss of stromal IL-33 leads to an increase in CD8+ T cell infiltration and activation, and, ultimately, reduced tumor growth.

Products